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Abstract 
Background: Approaches based on expression signatures of prostate cancer (PCa) have been proposed to predict 
patient outcomes and response to treatments. The transcription factor NF-Y participates to the progression from 
benign epithelium to both localized and metastatic PCa and is associated with aggressive transcriptional profile. The 
gene encoding for NF-YA, the DNA-binding subunit of NF-Y, produces two alternatively spliced transcripts, NF-YAs and 
NF-YAl. Bioinformatic analyses pointed at NF-YA splicing as a key transcriptional signature to discriminate between 
different tumor molecular subtypes. In this study, we aimed to determine the pathophysiological role of NF-YA splice 
variants in PCa and their association with aggressive subtypes.
Methods: Data on the expression of NF-YA isoforms were extracted from the TCGA (The Cancer Genome Atlas) data-
base of tumor prostate tissues and validated in prostate cell lines. Lentiviral transduction and CRISPR-Cas9 technol-
ogy allowed the modulation of the expression of NF-YA splice variants in PCa cells. We characterized 3D cell cultures 
through in vitro assays and RNA-seq profilings. We used the rank-rank hypergeometric overlap approach to identify 
concordant/discordant gene expression signatures of NF-YAs/NF-YAl-overexpressing cells and human PCa patients. 
We performed in vivo studies in SHO-SCID mice to determine pathological and molecular phenotypes of NF-YAs/NF-
YAl xenograft tumors.
Results: NF-YA depletion affects the tumorigenic potential of PCa cells in vitro and in vivo. Elevated NF-YAs levels 
are associated to aggressive PCa specimens, defined by Gleason Score and TNM classification. NF-YAl overexpres-
sion increases cell motility, while NF-YAs enhances cell proliferation in PCa 3D spheroids and xenograft tumors. The 
transcriptome of NF-YAs-spheroids has an extensive overlap with localized and metastatic human PCa signatures. 
According to PCa PAM50 classification, NF-YAs transcript levels are higher in LumB, characterized by poor prognosis 
compared to LumA and basal subtypes. A significant decrease in NF-YAs/NF-YAl ratio distinguishes PCa circulating 
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Background
Prostate cancer (PCa) is characterized by high clinical 
heterogeneity and multiple levels of molecular signatures 
[1]. Despite the predominant luminal-like phenotype 
observed in human patients [2], PCa seems to originate 
by both basal and luminal cells, the two main epithelial 
lineages of prostate gland. Transgenic mouse models 
have been used to understand the origin of PCa: basal- 
and luminal-origin tumors in inducible Pten-inactivated 
mice exhibited similar histopathology but significant 
different molecular signatures [3]. In particular, genes 
overexpressed in luminal-origin tumors were enriched 
in a lethal PCa signature generated by high-throughput 
expression profiling of prostate samples from a watch-
ful waiting patient cohort [4], consistently with a more 
aggressive phenotype of luminal-origin tumors. Inde-
pendent transcriptomic studies identified three PCa 
molecular subtypes: PCS1/Luminal B (LumB) tumors, 
which show high proliferation, poor differentiation 
and prognosis, PCS2/Luminal A (LumA) differentiated 
tumors with lipid and steroid biosynthetic signature, and 
PCS3/basal-cell-like subtype, characterized by extracel-
lular matrix (ECM) organization, inflammation and cell 
migration genes expression [5, 6].
The binding site for the heterotrimeric transcription 
factor (TF) NF-Y has been identified as biologically rel-
evant within the molecular network of genes up-regu-
lated during PCa progression, from benign epithelium 
to localized and hormone-refractory metastatic PCa [7]. 
These data perfectly agree with the over-representation 
of the NF-Y-binding motif, the CCAAT box, in promot-
ers of genes overexpressed in multiple types of cancers 
[8]. Moreover, studies on patients samples highlighted a 
correlation between the up-regulation of NF-Y subunits, 
NF-Y-target genes, cancer aggressiveness and poor prog-
nosis (for a review see [9]).
The gene encoding for the NF-YA DNA-binding 
subunit undergoes alternative splicing: skipping or 
inclusion of the second coding exon (exon 3) gives rise 
to NF-YA proteins with different molecular weights, 
namely NF-YA short (NF-YAs) and NF-YA long (NF-
YAl) [10]. The two proteins share the NF-YB/NF-YC 
interaction and the DNA binding C-terminal domains, 
while they  differ in the length of the N-terminal 
Glutamine-rich transactivation domain, with NF-YAl 
being 28/29 aa longer than NF-YAs. Tissue- and cell-
type specificity of the expression of the two isoforms 
has been clearly demonstrated [10, 11]. While in vitro 
assays suggested that the two isoforms have equal 
transcriptional activity [10, 11], recent reports have 
demonstrated that NF-YAs and NF-YAl are not func-
tionally equivalent [12–15]. In particular, NF-YAs lev-
els increase at the expense of NF-YAl in all subtypes of 
lung adenocarcinomas (LUAD) [16] and in the major-
ity of patients tissues of lung squamous cell carcinomas 
(LUSC), with NF-YAshigh subtypes being characterized 
by cell-cycle transcriptional signature and NF-YAlhigh 
tumors by a pro-migration transcriptional profile [17]. 
Similarly, in breast cancers the ratio between NF-YAs/
NF-YAl isoforms shifts towards NF-YAs, with the 
exception of aggressive and metastasis-prone basal-
like  Claudinlow tumors, which show high expression of 
NF-YAl together with typical epithelial to mesenchy-
mal transition (EMT) markers [18]. Finally, while NF-
YAs is undetectable in benign endometrial tissues, it is 
consistently expressed in high grade type I endometrial 
cancer (EC). Moreover, in low grade ECs, the presence 
of NF-YAs associated to low Lamin A levels is predic-
tive of poorly differentiated tumors and poor prognosis 
[19].
Altogether, these studies pointed at NF-YA splic-
ing as a key transcriptional signature that can improve 
patients’ stratification and better discriminate between 
different molecular subtypes. Likewise, here we show 
that NF-YA isoforms are differently expressed in PCa 
with respect to healthy prostate epithelial tissue and 
drives the formation of tumors with different pheno-
types. Modification of the expression of NF-YA splice 
variants, through lentiviral expression and CRISPR-
Cas9 technology in PCa cells, demonstrates that the 
two isoforms have distinct roles in viability, prolifera-
tion and invasion both in  vitro and in  vivo. The two 
NF-YA isoforms regulate different transcriptional 
cancer-associated programs, with NF-YAs-associated 
transcriptome overlapping with both localized and 
metastatic PCa. Our study demonstrates the differ-
ent contribution of the two NF-YA isoforms in PCa 
tumor cells from cancer cells in metastatic sites, consistently with pro-migratory function of NF-YAl. Stratification of 
patients based on NF-YAs expression is predictive of clinical outcome.
Conclusions: Altogether, our results indicate that the modulation of NF-YA isoforms affects prostate pathophysio-
logical processes and contributes to cancer-relevant phenotype, in vitro and in vivo. Evaluation of NF-YA splicing may 
represent a new molecular strategy for risk assessment of PCa patients.
Keywords: NF-Y, Prostate cancer, Alternative splicing, Genome editing, Transcriptome profiling
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progression and aggressiveness and highlights the 




RNA-seq and clinical data of TCGA- Prostate Adeno-
carcinoma (PRAD) dataset were retrieved from fireb 
rowse. org. The cohort was made of 498 tumor samples 
and 52 normal samples. Survival data were downloaded 
from UCSC Xena repository [20]. PAM50 classification 
on TCGA data were extracted from PCTA database for 
153 tumor samples (http:// www. thepc ta. org/ about/) [6], 
whereas the classification of remaining samples was pre-
dicted employing a deep learning based classification 
framework, DeepCC [21].
PCS classification of samples was determined accord-
ing to a highly specific 37 genes panel signature for PCS1, 
PCS2 and PCS3 [6]. Genes z-scores were calculated and 
for each PCS signature a median z-score was computed. 
Each sample was assigned to the PCS corresponding to 
the highest median z-score. RNA-seq raw data of meta-
static castration-resistant prostate cancer (Met. CRPC) 
samples and Circulating Tumor Cells (CTCs) were 
retrieved from Geodata, accession codes GSE147250 
and GSE104209 respectively. Both datasets were aligned 
against human transcriptome (GRCh37/hg19) using 
bowtie2 wrapper within RSEM 1.3.1 tool.
To compare gene expression of CRPC samples and 
CTCs, raw counts of both datasets were normalized 
with DESeq2 algorithm [22] and the Variance Stabilizing 
Transformed (vst) counts were used. As TCGA RNA-seq 
data employ a different gene annotation from Met. CRPC 
and CTCs datasets, DESeq2 normalization was not appli-
cable. Hence, we considered the ratio of NF-YA isoforms 
and we obtained box plots comparing processed TCGA 
RNA-seq data with the Met. CRPC dataset after log2 
transformation of TPM and z-score normalization.
Box plots were obtained using ggplot2 R package and 
significance of comparison was estimated with Wil-
coxon test. Survival analyses were performed employing 
survminer R package, where p values were computed 
according to the log-rank test. Cox proportional hazard 
regressions were computed with the finalfit R package. 
The analyses have been performed using R (v 4.0.5).
Cell lines and lentiviral transduction
Normal PNT1A (ECACC Cat# 95012614, 
RRID:CVCL_2163) were grown in RPMI 1640 Medium 
and Ham’s F12 Medium (1:1). Cancer DU145 (ATCC 
Cat# HTB-81, RRID:CVCL_0105) and LNCaP (ATCC 
Cat# CRL-1740, RRID:CVCL_1379) were grown in RPMI 
1640 Medium. Cancer PC3 cells (ATCC Cat# CRL-1435, 
RRID:CVCL_0035) were maintained in Ham’s F12 
Medium. All media (Biowest) were supplemented with 
2 mM glutamine, 100 IU/ml penicillin, 100 μg/ml strep-
tomycin and 10% FBS (Gibco). Normal RWPE-1 (ATCC 
Cat# CRL-11609, RRID:CVCL_3791) were grown in 
Keratinocyte Serum Free Medium (K-SFM; # 17005042, 
Gibco), supplemented with 0.05 mg/ml bovine pituitary 
extract (Gibco) and 5 ng/ml human recombinant epi-
dermal growth factor (Gibco). Cell lines were authenti-
cated by Short Tandem Repeat (STR) Analysis (Eurofins 
Genomics), verified to be mycoplasma free and passaged 
< 3 months. Healthy N1 cells and benign prostate hyper-
plasia C10 and C17 cells were a kind gift of Dr. A. Farsetti 
[23] and were cultured in IMDM Medium (Biowest) sup-
plemented with 10% FBS (HyClone). All cells were grown 
at 37 °C in a humidified incubator containing 5% CO2.
NF-YA inactivation was obtained by lentiviral infection 
of PC3 cells with pLKO.1/EGFP non-targeting shRNA 
(shCTR) or shRNA targeting exon 6 of NF-YA (shNF-
YA), previously described [24]. Cells were harvested 72 h 
post-infection (MOI = 20).
Stable NF-YA-overexpressing cell lines were obtained 
by lentiviral infection of PC3, LNCaP or DU145 cells 
with either pSIN-NF-YAs, pSIN-NF-YAl or control pSIN-
Empty particles and puromycin selection [13].
Anchorage‑dependent and anchorage–independent 
colony assays
Colony formation assays were performed as previously 
described [25]. For anchorage-dependent clonogenic 
assay, 1000 cells were seeded in 6 wells plates for 7 days 
and colonies were fixed and stained with 0.5% crystal vio-
let solution in 20% Methanol. For anchorage-independ-
ent colony formation assay, 2000 cells were resuspended 
in 0.25% agarose in complete cell growth medium and 
plated on top of a base layer (0.6% agarose). After 3 weeks 
(PC3) or 4 weeks (LNCaP) colonies were stained with 
0.07% crystal violet solution in 1X PBS. Plates were 
imaged and colonies were counted with automated col-
ony counter (OpenCFU 3.9.0).
Generation and culture of Multicellular Tumor Spheroids 
(MTSs)
5000 PC-3 cells were plated into 96-well Round Bot-
tom Ultra-Low Attachment (ULA) plates (#7007 and 
#4515, Corning) in 150 μl complete ice-cold medium 
containing 0.5 mg/ml Matrigel matrix (#354248, Corn-
ing) followed by centrifugation for 10 min at 1000×g, 
4 °C, using no braking. 2000 LNCaP cells were seeded 
into 96-well Round Bottom ULA plates in 200 μl com-
plete medium and centrifuged at 1000×g, 10 min. DU145 
cells were seeded into 96-well Round Bottom ULA 
plates in 200 μl complete medium containing 0.67 mg/ml 
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Matrigel matrix. MTSs were incubated for 7 days (PC3), 
14 days (LNCaP) or 10 days (DU145) at 37 °C, 5% CO2 
in humidified incubators. Fifty microlitres of fresh sphe-
roid medium was added every 4 days. MTSs images were 
acquired with an EVOS M5000 imaging system (Thermo 
Fisher Scientific) and analysed with ImageJ software for 
manual and automated measurements of projected areas 
[26].
Analysis of cell proliferation and viability
Cell viability in transduced shCTR/shNF-YA cells was 
measured by colorimetric 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay [25].
Cell viability of MTSs was assessed using LIVE/DEAD 
imaging. Spheroids were incubated for 1 h in PBS con-
taining 1 μM Calcein-AM (#80011, Biotium) and 2 μM 
Propidium Iodide (PI). The samples were then imaged 
with an EVOS M5000 fluorescence microscope (Thermo 
Fisher Scientific) with a 4X objective and a Nikon A1 
confocal laser scanning microscope.
Cell proliferation in MTSs was assessed by cytofluori-
metric analysis. Spheroids were cultured for 7 days and 
20 μM BrdU was added for the final 16 h. Single cell sus-
pension was then obtained by incubation in warm 0.25% 
Trypsin-EDTA, at 37 °C, for 10 min, pipetting up and 
down 10 times every 3 min and 30 times at the end of 
incubation, to help dissociation. After washing with 1X 
PBS/0.5% Tween-20, cells were treated with 2 N HCl for 
30 min at RT, followed by the addition of 0.1 M borate 
buffer (pH 8.5) for 5 min, RT. Cells were then washed 
and incubated with mouse anti-BrdU antibody (#347580, 
BD Biosciences) for 1 h at 4°C. After washing, cells were 
incubated with FITC anti-mouse secondary antibody 
(#F0313, Agilent Dako) for 1 h at 4C, washed in 1X PBS 
and resuspended in citrate solution (Na–Citrate 3.4 mM, 
NaCl 9.65 mM, NP-40 0.03%). Apoptotic cells were 
stained with AnnexinV-FITC (#V13242, Invitrogen), 
according to the manufacturer’s protocol. BrdU-positive 
and AnnexinV-positive cells were analyzed by an Attune 
Nxt cytofluorimeter (Thermo Fisher Scientific).
Whole‑mount Immunostaining of MTSs
MTSs were carefully handled with cut P200/P1000 
pipette tips and entire procedure was performed in sus-
pension, allowing MTSs to settle under gravity on ice, to 
preserve morphology. MTSs were washed with 1X PBS 
and fixed in 10% Formalin Solution (#HT5014, Sigma-
Aldrich) for 20 min, RT. After washing with 1X PBS, 
MTSs were permeabilized with ice-cold 1X PBS/0.5% 
TritonX-100 for 10 min at RT and incubated 10 min in 
blocking buffer (3.5% BSA, 0.1% TritonX-100 in 1X PBS). 
MTSs were incubated over-night at 4 °C with anti-Ki-67 
(dilution 1:300 in blocking buffer; #9129, Cell Signaling). 
After two washes with 1X PBS for 5 min, Alexa-fluor 
488-conjugated antibody (dilution 1:400 in blocking 
buffer; #A-21206, Thermo Fisher Scientific) was incu-
bated for 2 h at RT, followed by nuclei staining with DAPI 
(1:5000 in 1X PBS) for 10 min. After washing with 1X 
PBS, MTSs were mounted on slides with imaging spacers 
in Mowiol. Images were acquired using an EVOS M5000 
(Thermo Fisher Scientific) fluorescence microscope.
RNA‑seq and gene expression analysis of MTSs
Eighteen MTSs per cell line were pooled and RNA for 
sequencing was extracted by automatic extractor Max-
wellRSC (simply RNA Cells kit, Promega). Three inde-
pendent experiments were performed. RNA-seq libraries 
preparation and sequencing were performed as previ-
ously described [27]. RNA-seq raw data were aligned 
against human transcriptome (GRCh37/hg19) using 
bowtie2 wrapper within RSEM 1.3.1 tool. Significant dif-
ferential expressed genes (DEGs) were computed with 
DESeq2 setting FDR < 0.01 and |Log2FC| > 1 in R envi-
ronment. Unique DEGs for one comparison, e.g. Short 
vs Empty, were obtained starting from its total DEGs and 
filtering out genes shared with the other comparison, 
e.g. Long vs Empty, having |Log2FC| > 0.5. Gene Ontol-
ogy enrichment on DEGs was performed using KOBAS 
3.0 (http:// kobas. cbi. pku. edu. cn/ anno_ iden. php) and top 
25 terms with FDR < 0.001 were kept. More general GO 
terms, namely those with background number of genes 
higher than 500, were discarded. Rank-Rank Hypergeo-
metric Overlap (RRHO) was performed with RRHO2 R 
package by ranking Log2FC of all differential expressed 
genes for each comparison.
Migration and invasion assays
The migration and invasion assays were performed with 
Transwell membranes (pore size 8 μm; #3464, Corning) 
without coating (migration assay) or coated with 50 μl 
of 1 mg/ml Matrigel (#354248, Corning) in serum-free 
medium (invasion assay). PC3 cells were starved over-
night and 5 ×  104 cells were seeded in 100 μl of serum-
free medium into the upper chamber of the transwell. 
Complete F12 medium containing 10% FBS was used 
as chemoattractant in the lower chamber. After 18 h 
(migration assay) or 26 h (invasion assay), the cells were 
removed with a cotton swab from the upper chambers, 
while cells on the underside of the inserts were fixed and 
stained with 0.5% crystal violet solution in 20% Methanol, 
for 15 min. Five randomly selected fields were counted 
under a light microscope and percent migration/invasion 
was calculated according to the manufacturer’s protocol.
For wound healing cell migration assay, PC3 cells were 
seeded into Ibidi culture-insert (#80209, Ibidi GmbH). 
Cells were cultured for 24 h and then the culture-insert 
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was removed to create the gap. Cells were gently washed 
with 1X PBS and complete growth medium was pro-
vided. Images were acquired immediately after removal 
of the insert and over 22 h. Wound areas were measured 
using Photoshop software and residual wound area (%) 
was calculated with the formula: (final area/initial area 
× 100).
3D spheroid invasion assays were performed in (i) 
growth factors–enriched conditions and (ii) chemotactic 
conditions: (i) spheroids were assembled by plating 2000 
PC3 cells in 96-well Round Bottom ULA plates (#4515, 
Corning). After 3 days, Matrigel matrix (#354248, Corn-
ing) was added to each well to 1 mg/ml final concentra-
tion. Optical microscopy images were taken after 7 days 
and the area (A) of whole and core spheroids was calcu-
lated with Photoshop software. Spheroid invasion index 
(%) was calculated with the formula:  (Atot -  Acore)/Atot 
× 100. (ii) MTSs were generated by centrifugation of 
5000 PC3 cells into 96-well Round Bottom ULA plates 
(#7007 and #4515, Corning), in complete growth medium 
containing 0.5 mg/ml Matrigel matrix (#354248, Corn-
ing), as described above. After 7 days, MTSs were gently 
collected and washed with 1X PBS, using cut P200/P1000 
pipette tips to preserve morphology. MTSs were embed-
ded into 5 mg/ml Growth Factor Reduced Matrigel 
(#354230, Corning) diluted in F12 medium containing 1% 
FBS. One 50 μl drop containing one MTS was dispensed 
in a 24-well plate and allowed to polymerize into a 37 °C 
incubator. Embedded spheroids were then submerged in 
F12 warm culture medium containing 10% FBS as chem-
oattractant. Invasion was assessed after 7 and 11 days by 
optical microscopy with an EVOS M5000 imaging system 
(Thermo Fisher Scientific).
In vivo mouse xenograft study
Male SCID Hairless Outbred (SHO) mice (Strain Code 
#474, Charles River Laboratories) were kept under proto-
cols approved by the Institutional Animal Care Commit-
tee and by National Institute of Health (Ministero della 
Salute) (n. 709/2017-PR). Six groups of mice were estab-
lished: transduced shCTR and shNF-YA PC3 cells (n = 7/
each), stable PC-3 Empty, NF-YAl, NF-YAs (n = 8/each) 
and NF-YAs-only (n = 6). 5 ×  105 PC3 cells mixed at a 
1:1 dilution with Matrigel HC (#354248, Corning) were 
sub-cutaneously flank-injected: the length and width of 
the xenografts were measured once a week with a digi-
tal caliper and tumor volumes were estimated using the 
formula V = 0.5 × a ×  b2, where a and b are the largest 
and smallest diameters, respectively. The rate of growth 
was calculated using the following formula: (Vol 2-Vol 
1)/Vol 1 × 100%, where Vol2 = tumor volume on meas-
ured week; Vol1 = tumor volume on previous week [28]. 
After 5 weeks, animals were sacrificed and tissues were 
harvested. The tumor specimens were divided into two 
parts, one for snap freezing in liquid nitrogen for pro-
tein/RNA extraction, the other was fixed in 10% for-
malin solution for 24 h and embedded in paraffin for 
histopathological analyses. Lung samples were collected 
and fixed in 10% Formalin Solution (#HT5014, Sigma-
Aldrich) for 24 h at 4 °C and frozen.
Histology and immunohistochemistry (IHC) on FFPE 
sections
Histopathology and IHC evaluation were performed 
by a pathologist on formalin-fixed and paraffin-embed-
ded (FFPE) tumor sections. For histological analysis of 
tumor spheroids, handling of MTSs was carefully per-
formed with cut P200/P1000 pipette tips, to preserve 
morphology. MTSs were fixed in 10% Formalin Solution 
(#HT5014, Sigma-Aldrich) over night at 4 °C, washed 
in PBS and embedded in 1% agarose gel in Peel-A-Way 
embedding molds (#E6032, Sigma-Aldrich). The thin 
agarose blocks containing MTSs were dehydrated and 
paraffin embedded. Four micrometres FFPE sections 
were prepared and stained with standard Haematoxylin 
and Eosin (H&E). For analysis of xenograft tumor tis-
sues, 3,5 μm-thick sections were prepared and stained 
following standard H&E automatic procedure routinely 
adopted by the Anatomic Pathology laboratory (Leica 
Biosystems). Immunohistochemical analysis of Ki-67 
(MIB1 clone, dilution 1:100; #M7240, Dako) was per-
formed using a Bench Mark ULTRA automated stainer 
(Ventana Medical Systems). Ki-67 label index was meas-
ured by pathologist visual scoring, as the percentage of 
tumor cells immunoreactive for Ki-67 over the total 
number of tumor cells. Mean values were obtained by 
scanning overall tumor masses, observed under 40X 
optical microscope.
Protein extraction and Immunoblotting
Whole-cell protein extracts were prepared by lysis of 
2D cultured cells into 1X SDS sample buffer (25 mM 
Tris–HCl pH 6.8, 1.5 mM EDTA, 20% glycerol, 2% SDS, 
5% b-mercaptoethenol, 0.0025% Bromophenol blue). 
Protein lysates of MTSs were obtained from a pool of at 
least eight spheroids, through a two step lysis procedure: 
MTSs’ proteins were extracted in RIPA buffer (50 mM 
Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton 
X-100, 0.1% sodium deoxycholate, 0.1% SDS, 0.5 mM 
PMSF and protease inhibitor cocktail) for 30 min on ice 
and then one volume of 2X SDS sample buffer was added 
to the samples for complete lysis. Protein lysates from 
tumor xenografts were obtained in RIPA buffer with 
protease and phosphatase inhibitors, on ice, using a pot-
ter homogenizer. Homogenates were incubated on ice 
Page 6 of 23Belluti et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:362 
for 30 min, and then sonicated 2 min (in rounds of 10 s 
sonication/10 s rest for each cycle, on ice). Extracts were 
then cleared by centrifugation at > 10,000 x g for 30 min 
at 4 °C.
Equivalent amounts of cellular extracts were resolved 
by SDS-PAGE, transferred to PVDF membrane with 
Trans-Blot Turbo Transfer System (Bio-Rad) and 
immunoblotted with the following primary antibodies, 
diluted 1:1000 in 1X TBS with 1 mg/ml BSA: anti-NF-
YA (#17753, Santa Cruz Biotechnology), anti-Tubulin 
(#66031, Proteintech Europe), anti-AKT (#MAB2055, 
R&D Systems) and anti-phospho-AKT(S473) (#AF887, 
R&D Systems). Membranes were blotted and scanned 
with an Amersham Imager AI680 RGB (GE Healthcare), 
using detection reagents Westar ηC and Supernova HRP 
substrates (Cyanagen).
RNA extraction and RT‑qPCR
Xenograft tumor tissues were lysed with Tri-Xtract™ rea-
gent (#786–652, G-Biosciences) using a polytron homog-
enizer (POLYTRON® PT 10–35, Kinematica). RNA was 
further purified with Ribospin II mini Kit (#314–150, 
GeneAll), according to the manufacturer’s protocol. Two 
hundred nanograms of RNA were retrotranscribed with 
PrimeScript RT Reagent Kit (#RR037A, Takara Bio) and 
quantitative PCR was performed with SsoAdvanced Uni-
versal SYBR Green Supermix (#1725274, Bio-Rad), using 
a Biorad CFX Connect™ Real-Time PCR Detection Sys-
tem. Data were analyzed using the Bio-Rad CFX Maestro 
2.0 software (Bio-Rad) and mRNA expression was nor-
malized to RPS20 and bACTIN genes. Oligonucleotides 
are listed in Supplementary Table S1.
Extraction of genomic DNA and Alu‑qPCR
Genomic DNA was extracted from formalin-fixed 
mouse lungs using a heat and alkaline protocol previ-
ously described [29]. Briefly, lungs were minced and 
DNA extraction/reverse cross-link was performed in 
alkali digestion buffer (0.1 M NaOH, 1% SDS), at 100 °C 
for 40 min. DNA was purified and resuspended in TE 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). Twenty 
nanograms genomic DNA was used in qPCR reactions, 
with highly sensitive and specific human Alu primers 
previously described [30] (Supplementary Table S1), in a 
total reaction volume of 20 μl with SsoAdvanced Univer-
sal SYBR Green Supermix (#1725274, Biorad). PCR was 
performed on a Biorad CFX Connect™ Real-Time PCR 
Detection System, under the following conditions: 1 cycle 
of 95 °C for 10 min, followed by 50 cycles of 95 °C for 15 s, 
56 °C for 30 s and 72 °C for 30 s. qPCR threshold of detec-
tion was set so that the Cq values of negative controls 
(mouse DNA) or low amount of human genomic DNA 
outside the linear range of amplification were higher than 
this threshold value, set at 1 cycles below the Cq value of 
negative controls.
CRISPR/Cas9 gene editing
To knockdown the expression of both long and short 
splicing variants of human NF-YA we employed the 
CRISPR/Cas9 system. sgRNA was designed to guide 
Streptococcus pyogenes Cas9 (SpCas9) to a 5′-TGG-
3′ PAM sequence in exon 2 of the human NF-YA gene. 
To generate pX330.gRNA.PGK.GFP, we first cloned the 
designed sgRNA in the pX330-U6-Chimeric_BB-CBh-
hSpCas9 plasmid (Addgene plasmid #42230; http:// n2t. 
net/ addge ne: 42230; RRID:Addgene_42,230) [31] by oligo 
annealing into BbsI sites (oligonucleotides are listed in 
Supplementary Table  S1). Then, an expression cassette 
for GFP reporter gene under the control of the strong 
constitutive phosphoglycerate kinase promoter (PGK) 
was subcloned in pX330 plasmid downstream of the 
polyA signal of SpCas9 expression cassette. Control plas-
mid without gRNA was generated as described for effec-
tor plasmid.
NF-YAl or NF-YAs PC3 cells were transfected with 
either the effector or control plasmids using FuGENE HD 
Transfection Reagent (#E2311, Promega), with a plasmid: 
FuGENE HD ratio of 1:3.5, according to the supplier’s 
protocol. Cultures were visualized through fluorescence 
microscopy 48 h post-transfection and cells were then 
harvested in culture media at final concentration of 
 1x106cells/ml: GFP positive cells were sorted by FAC-
SARIA III flow cytometer (BD Biosciences) equipped 
with two air-cooled lasers at 488 and 633 nm wave-
lengths. Data were analysed by Diva software (BD Bio-
sciences). Monoclonal cell populations were then isolated 
by limiting dilution into 96-well plates.
To analyze editing efficiency in treated cells, genomic 
DNA was extracted from CRISPR-treated NF-YAs or 
NF-YAl PC3 cells or clones, using QIAamp DNA mini 
or micro kits (Qiagen) following the manufacturer’s 
instructions. Human and mouse genomic regions flank-
ing sgRNA target site were amplified by PCR using PCR 
GoTaq (Promega) (oligonucleotides are listed in Supple-
mentary Table  S1). Then, PCR amplicons were Sanger 
sequenced and analyzed by TIDE (Tranking of Indels 
decomposition, https:// tide. nki. nl) software to evaluate 
the frequency of indels generated upon NHEJ-repair of 
CRISPR-mediated DSBs.
Statistical analysis
All statistical analyses were performed with GraphPad 
PRISM 6 software (GraphPad Prism, RRID:SCR_002798), 
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using unpaired t-test, multiple t-test, one-way ANOVA 
and two-way ANOVA with post-hoc tests, as specified in 
the figure legends. Graphs represent Means ± Standard 
Error of the Mean (SEM) and specific number of biologi-
cal replicates (n values) are reported in each figure leg-
end. Data are considered to be statistically significant 
if p  < 0.05 (*), p  < 0.01 (**), p  < 0.001(***) and p  < 0.0001 
(****).
Results
Higher expression and altered splicing signature of NF‑YA 
are associated to PCa aggressiveness
To identify whether global gene expression of NF-Y subu-
nits is deregulated in PCa, RNAseq data were extracted 
from the TCGA (The Cancer Genome Atlas) database 
of tumor prostate tissues and compared to healthy ones. 
While NF-YA expression is significantly up-regulated in 
PCa samples, NF-YB and NF-YC subunits show decreased 
transcript levels (Fig. 1A). This opposite behavior is con-
sistent with our previous results showing that a negative 
feedback loop controls the transcription of NF-Y subunits, 
with NF-YA down-regulation triggering NF-YB/NF-YC 
up-regulation and vice versa [32]. Therefore, we focused 
our attention on the NF-YA DNA-binding subunit, and 
we evaluated whether a correlation exists between NF-YA 
transcript levels and PCa grade and aggressiveness, deter-
mined by Gleason Score (GS). NF-YA expression propor-
tionally raises with increasing GS (Fig.  1B). Moreover, 
NF-YA transcription is up-regulated in more aggressive 
pathological T (Tumor) stages, with T1 and T2 describ-
ing a organ-confined cancer, T3-T4 representing cancer 
spreading outside the prostate (Fig.  1C). We also identi-
fied that NF-YA increases in pathological N1 with respect 
to N0 stages, where N (Node) stage N1 means that the 
cancer has spread from the primary tumor to lymph 
nodes near the prostate (Fig. 1D).
As previously described, the NF-YA gene generates two 
spliced isoforms, which show different expression levels 
depending on tissue type, proliferation/differentiation 
and normal/tumor conditions [13, 14, 16–19, 33]. TCGA 
RNAseq data showed a significant increase in NF-YAs 
transcripts at the expense of NF-YAl in tumor prostate 
tissues compared to healthy ones (Fig. 1E). In particular, 
the increasing trend of NF-YAs showed a direct correla-
tion with GS (Fig.  1F) and pathological T and N stages 
(Fig. 1G, H).
Altogether, these analyses suggested a possible contri-
bution of NF-YA overexpression in PCa and pointed out 
a splicing signature associated to PCa progression, with 
NF-YAs being mostly expressed in more aggressive can-
cer types.
NF‑YA abrogation attenuates PCa‑related cellular processes
We then decided to investigate whether the expression 
of NF-YA isoforms is altered in cancer epithelial prostate 
cells compared to normal ones. Western blot analysis of 
total cellular extracts from different prostate cell lines 
clearly showed that healthy (N1) and benign hyperpla-
sia (BPH) cells (C10, C17) almost exclusively express the 
longer NF-YA variant (NF-YAl) (Fig.  2A) [23]. NF-YAs 
was well detectable in SV40-immortalized PNT1A nor-
mal luminal cells, HPV-immortalized RWPE-1 normal 
basal cells and highly expressed in both androgen-unre-
sponsive (PC3 and DU145) and androgen-responsive 
(LNCaP) cancer cells derived from different PCa metas-
tastic sites [34]. The NF-YAs/NF-YAl ratio measured by 
qRT-PCRs perfectly matched with protein expression of 
NF-YA isoforms (Fig. 2B), indicating that gene transcrip-
tion regulates NF-YAs and NF-YAl cellular levels.
The importance of NF-YA in cancer-associated cel-
lular processes has been highlighted in various cellu-
lar contexts and NF-YA knock-down triggers cell cycle 
arrest and apoptotic cell death [9, 16–18, 35–37]. There-
fore, we decided to analyze the effect of NF-YA knock-
down in PC3 prostate cancer cells derived from a bone 
metastasis that show features of highly aggressive small 
cell neuroendocrine carcinoma (SCNC), an aggressive 
histological subtype of CRPC (metastatic castration-
resistant prostate cancer). Lentiviral delivery of shRNAs 
led to high efficiency of gene inactivation (Fig.  2C) and 
time-course MTT analysis showed a slight but significant 
reduction in cellular proliferation of shNF-YA cells com-
pared to shCTR ones (Suppl. Fig. 1A). We then evaluated 
Fig. 1 Expression of NF-YA and its splice variants in prostate cancer samples. A Expression levels of NF-YA, NF-YB and NF-YC measured as transcripts 
per million (TPM) in prostate adenocarcinoma (PRAD) patients compared to normal ones. N = normal samples, T = tumor samples. Wilcoxon test T 
vs N: **p < 0.01, ****p < 0.0001. B Transcript levels (TPM) of NF-Y subunits in PRAD patients according to Gleason Score stratification. Wilcoxon test 
T vs N:  **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant. Jonckheere trend test: §§§§p < 0.0001. C NF-YA expression levels in PRAD samples 
stratified by pathological T stage. Jonckheere trend test: §§§§p < 0.0001. D NF-YA expression levels in PRAD samples stratified by pathological N stage. 
Wilcoxon test N1 vs N0: **p < 0.01. E Transcript levels (TPM) of NF-YAs and NF-YAl in PRAD patients compared to normal ones from TCGA data set. 
N = normal samples, T = tumor samples. Wilcoxon test T vs N: ****p < 0.0001. F TPM of NF-YAs and NF-YAl in PRAD patients according to Gleason 
Score stratification. Wilcoxon test: **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant. Jonckheere trend test: §§§§p < 0.0001. G Transcript 
levels (TPM) of NF-YA isoforms according to pathological T stage. Jonckheere trend test: §§§§p < 0.0001. H Transcript levels (TPM) of NF-YA isoforms 
according to pathological N stage. Wilcoxon test N1 vs N0: *p < 0.05, **p < 0.01
(See figure on next page.)
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the effect of NF-YA abrogation on cancer-related cellular 
processes, such as clonal growth, migration and inva-
sion abilities. The soft agar colony formation assay high-
lighted a clear impairment in anchorage-independent 
growth of NF-YA-inactivated cells when compared to 
control cells (Fig. 2D). Additionally, NF-YA loss induced 
severe defects in migration and invasion abilities of PC3 
cancer cells, as demonstrated by measurements in Tran-
swell two-chamber system with FBS as chemoattractant 
(Fig. 2E and F).
Finally, we verified whether NF-YA depletion affects 
the tumorigenic potential of PC3 cells in vivo. Scramble 
and shNF-YA-infected PC3 cells were sub-cutaneously 
(s.c.) injected into immune-compromised mice and xen-
ograft tumor growth was monitored for 5 consecutive 
weeks. NF-YA loss severely impaired tumor incidence 
and growth of engrafted tumors (Fig.  2G, H and Suppl. 
Fig. 1B).
These results demonstrated the important role of 
NF-YA expression in PCa-associated phenotype.
NF‑YAs overexpression enhances cell proliferation of PCa 
cells within three‑dimensional multicellular spheroids
To understand whether NF-YAs, compared to NF-YAl, 
has unique properties in conferring aggressiveness to PCa, 
we generated PC3 (Fig.  3A), LNCaP and DU145 (Suppl. 
Fig. 2A, E) cell lines stably overexpressing NF-YA isoforms 
through transduction of NF-YAs- and NF-YAl- lentiviral 
particles. A decrease in clonal expansion was observed in 
NF-YA-overexpressing cells when cultured in anchorage-
dependent (Fig.  3B and Suppl. Fig.  2B) and anchorage-
independent conditions (Fig. 3C and Suppl. Fig. 2C).
To better understand the differences induced by NF-
YAs and NF-YAl in PCa cells, we took advantage of 
in vitro 3D models that closely reproduce relevant tumor 
conditions for complex cell–cell and cell–matrix interac-
tions. Multicellular tumor spheroids (MTSs) were grown 
in scaffold-based or -free conditions, depending on the 
ability of PCa cell lines to spontaneously form spheroids 
in anchorage-independent circumstances. NF-YAs over-
expression increased spheroids size of PC3 (Fig.  3D), 
LNCaP and DU145 (Suppl. Fig. 2D, F).
We assessed cell proliferation and viability in MTSs 
through Ki-67 and Calcein-AM/Propidium Iodide (live/
dead) stainings: all MTSs showed an external prolif-
erating zone and an internal necrotic area (Fig.  3E, 
upper and middle panels). Cytofluorimetric analysis of 
BrdU-stained-cells was then performed: a higher per-
centage of BrdU-positive cells was detected in NF-YA-
overexpressing MTSs, in particular in NF-YAs-spheroids 
(from 18.9% in Empty to 26.4 and 33.6% in NF-YAl and 
NF-YAs, respectively) (Fig.  3F), hinting at increased 
proliferation rate induced by NF-YAs overexpression. 
Significant decrease of apoptotic/necrotic Annexin 
V-positive cells was observed in both NF-YAl- and NF-
YAs-MTSs (Fig.  3G). The increase in activated AKT, 
detected by phosphorylation at Ser473 in MTS extracts, 
was consistent with a major activity in cell proliferation 
for NF-YAs with respect to NF-YAl (Suppl. Fig. 2G).
Interestingly, morphological analysis of Calcein-AM/
Propidium Iodide-stained MTSs by confocal microscopy 
(Fig. 3E, lower panel), optical microscopy and hematoxy-
lin and eosin staining (H&E) (Fig.3H, I) showed dramatic 
phenotypic alterations with budding and ring-shaped 
structures in NF-YAs-MTSs.
Taken together, these findings demonstrate that NF-
YAs enhances cell proliferation and triggers unique 
cell-ECM interactions in three-dimensional culture con-
ditions recapitulating complex interactions.
NF‑YAs expression is required for PCa cell viability
Although the levels of endogenous human NF-YAs or 
NF-YAl could be considered negligible compared to the 
overexpressed murine isoform (human-mouse protein 
identity = 99%) (Fig.  3A), we knocked down the expres-
sion of endogenous NF-YA gene to definitely ascribe 
phenotypic alterations to isoform-specific activities. 
We designed a sgRNA to guide Streptococcus pyogenes 
(See figure on next page.)
Fig. 2 Effects of NF-YA inactivation in tumor prostate cells. A Expression of NF-YA splice variants in prostate epithelial normal and cancer cells 
by western blot analysis of total cellular extracts. N1 = primary healthy epithelial prostate cells, C10, C17 = primary BPH prostate cells. RWPE-1, 
PNT1A = normal immortalized cell lines. PC3, DU145, LNCaP = PCa cell lines. Tubulin was used as loading control of total cellular extracts. B 
Expression levels of NF-YA isoforms quantified by RT-qPCR and reported as fold change of NF-YAs/NF-YAl mRNA ratio vs N1 cell line levels, arbitrarily 
set at 1. Rpl21 was used as reference gene. C Western blot analysis of NF-YA expression in PC3 cells untreated (CTR) or infected with scramble 
(shCTR) or NF-YA-targeting shRNA (shNF-YA). Tubulin was used as loading control. D Colony number of shCTR and shNF-YA cells cultured in 
anchorage-independent growth conditions. Data represent mean ± SEM (unpaired t-test: ***p < 0.001, n = 4). E Percentage of cell migration of 
shCTR and shNF-YA cells measured by transwell assay. Data represent mean ± SEM (unpaired t-test: *p < 0.05, n = 3). F Percentage of cell invasion 
of shCTR and shNF-YA cells measured by transwell assay. Data represent mean ± SEM (unpaired t-test: **p < 0.01, n = 2). G Representation of tumor 
incidence after 5 weeks from s.c. injection of shCTR and shNF-YA PC3 cells into SCID Hairless Outbred (SHO®) mice. H (Left panel) Volumes  (mm3) 
of shCTR and shNF-YA xenografted tumors at the indicated time points. Data represent mean ± SEM (two-way ANOVA with Holm-Sidak’s test: 
**p < 0.01, ***p < 0.001, ****p < 0.0001, n = 7). (Right panel) Tumor weight of xenografted tumors isolated after 5 weeks from cell inoculation. Data 
represent mean ± SEM (unpaired t-test: **p < 0.01)
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Cas9 (SpCas9) to a 5′-TGG-3′ PAM sequence present 
on the reverse complementary strand of human NF-YA 
exon 2 (Suppl. Fig.  3A). NF-YAs and NF-YAl PC3 cells 
were transfected with control or effector plasmids for 
the expression of CRISPR/Cas9 components and GFP 
reporter gene, and analyzed for frequency of editing 
2 days post-transfection by TIDE analysis. CRISPR-
treated PC3 cells showed about 38% transfection effi-
ciency in both NF-YAs and NF-YAl cells. We observed 
up to 12.9% editing on the human NF-YA gene (Suppl. 
Fig. 3B), without detectable indel frequency on the over-
expressed murine isoforms (Suppl. Fig.  3C). To enrich 
for edited cells, we sorted GFP+ transfected cells by flow 
cytometry and isolated monoclonal cell populations. The 
number of CRISPR-edited clones for NF-YAl cells was 
dramatically reduced compared to NF-YAs ones (6% vs 
41%, respectively, in 3 experiments). TIDE analysis of 
NF-YAl edited clones did not identify biallelic NF-YA 
deletion, while 82% of NF-YAs edited clones harbored 
biallelic deletion. These results indicate that cells express-
ing uniquely NF-YAl (NF-YAl-only) cannot survive, dif-
ferently from the cells expressing NF-YAs-only. We thus 
selected two NF-YAs-only clones for further analyses 
(Fig. 4A and Suppl. Fig. 3D). The clones showed morpho-
logical characteristics similar to NF-YAs MTSs (Fig. 4B). 
Additionally, NF-YAs-only cells formed tumors in  vivo 
with 100% incidence and a tumor growth similar to NF-
YAs xenograft tumors (Fig. 4C).
These results suggest a unique role for NF-YAs in PCa 
cell viability.
The transcriptional profiles activated by NF‑YAs and NF‑YAl 
differently overlap with human localized or metastatic PCa 
signatures
To shed light on the transcriptional effects induced by 
NF-YA isoforms, leading to different tumor phenotypes, 
we performed RNA-seq profilings of transduced cells 
cultured as MTSs. Compared to Empty-cells, 872 and 
620 differentially expressed genes (DEGs) were retrieved 
in NF-YAl cells, and 962 and 686 genes were found in 
NF-YAs cells as up- and down-regulated, respectively. 
The analysis of Gene Ontology enrichment (GO< 500 
and |Log2FC| > 1) (Fig.  5A and Suppl. Fig.  4) showed 
that GO Terms up-regulated in NF-YAl cells are associ-
ated to neuron differentiation and nervous system, uro-
genital development, cell morphogenesis, extracellular 
matrix (ECM) and positive regulation of cell motility/
migration. The overexpression of NF-YAs induced the 
up-regulation of gene categories related to ECM organi-
zation, angiogenesis and blood vessels morphogen-
esis, cell motility/migration and locomotion. Since some 
terms were common between NF-YAl and NF-YAs tran-
scriptional profiles, we performed a selective analysis 
of NF-YAl vs Empty unique DEGs by filtering out genes 
with |Log2FC| > 0.5 in NF-YAs vs Empty, and vice versa 
for NF-YAs vs Empty unique DEGs, discarding genes 
with |Log2FC| > 0.5 in NF-YAl vs Empty (Suppl. Fig.  5). 
Categories associated to cell differentiation, in particular 
neuron differentiation, were still retrieved among NF-YAl 
up-regulated GO terms (Suppl. Fig. 5A, left panel), while 
NF-YAs confirmed mainly ECM component and organi-
zation as increased gene products (Suppl. Fig.  5B, left 
panel).
The ECM signature clearly hints at a role for NF-
YAs in modulating the interaction between epithelial 
cells and the environment, which is consistent with the 
budding ring-shaped structures previously described 
(Fig. 3H, I) but also suggestive of an invasive phenotype. 
In order to identify whether the NF-YA splicing signa-
ture could correlate with PCa aggressiveness and meta-
static potential, we surveyed genes highly expressed in 
localized vs benign and metastatic vs localized human 
tumors data sets [38] and checked for concordant and 
discordant gene expression signatures using an updated 
rank-rank hypergeometric overlap (RRHO) approach 
[39]. RRHO heatmaps showed anti-correlation between 
genes overexpressed in NF-YAl vs NF-YAs and those 
upregulated in localized vs benign samples (Fig.  5B). 
An extensive biologically relevant overlap was observed 
between the signature of metastatic vs localized tumors 
Fig. 3 Effects of stable overexpression of NF-YA isoforms in tumor cells. A Western blot analysis of total extracts from PC3 cells stably infected with 
Empty, NF-YAl and NF-YAs lentiviral particles. Tubulin was used as loading control. B, C Colony number of Empty, NF-YAl and NF-YAs stable cell lines 
in anchorage-dependent and anchorage-independent conditions, respectively. Data represent mean ± SEM (one-way ANOVA with Fisher’s LSD test: 
*p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant, n = 6). D Size of Empty, NF-YAl and NF-YAs MTSs calculated as projected area at the indicated 
time points. Data represent mean ± SEM (two-way ANOVA with Holm-Sidak’s test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n between 8 and 
68 spheroids from 8 independent experiments). E Representative immunofluorescence images of Ki67/Dapi and Calcein-AM/PI staining performed 
on Empty, NF-YAl and NF-YAs MTSs. Scale bar = 500 μm. The lower panel shows details of Calcein-AM/PI staining by confocal microscopy. Scale 
bar = 50 μm. F Percentage of BrdU-positive cells following incubation of MTSs with 20 μM BrdU for 16 h. Data represent mean ± SEM (one-way 
ANOVA with Fisher’s LSD test: **p < 0.01, ****p < 0.0001, n = 4). G Percentage of AnnexinV-positive cells identified by cytofluorimetric analysis 
of MTSs. Data represent mean ± SEM (one-way ANOVA with Fisher’s LSD test: *p < 0.05, ns, not significant, n = 3). H Optical microscopy images 
representative of Empty, NF-YAs and NF-YAl MTSs morphology. Scale bar 4X = 500 μm, scale bar 10X = 250 μm (I) Representative images of H&E 
stained sections of MTSs. Scale bar = 100 μm
(See figure on next page.)
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and genes highly expressed in both NF-YAl and NF-YAs 
(Fig. 5C).
These results suggest that NF-YAs expression charac-
terizes localized tumors, while both NF-YAs and NF-YAl 
could be involved in the metastatization process.
Effect of NF‑YAs and NF‑YAl overexpression on PCa 
malignant features in vivo
We then used NF-YA transduced cells for mouse xeno-
graft studies to investigate whether the above described 
properties were obvious also in  vivo. Equal number of 
exponentially growing PC3 cells were injected s.c. into 
SCID Hairless mice and tumor volumes were deter-
mined (Suppl. Fig.  6A, B). Both NF-YAs and NF-YAl 
overexpression significantly reduced tumor weights at 
5 weeks post-injection (Fig.  6A). Taking into considera-
tion that very few injected PC3 cells initiate the tumor 
[40], reduced tumor size could be the consequence of 
decreased clonal ability observed in NF-YA-transduced 
cells (Fig. 3B, C). Indeed, the analysis of growth ability of 
engrafted cells, evaluated as rate of growth (%), showed 
similar kinetics in NF-YA-overexpressing tumors com-
pared to Empty-ones from week 4 (Fig.  6B). Moreo-
ver, we observed a lag in the growth of NF-YAs tumors 
before the exponential phase, which could be the conse-
quence of the complex cell-ECM interaction previously 
described. We decided to process xenograft tumors for 
histopathological analysis with routine H&E staining and 
Ki-67 immunohistochemistry (Fig.  6C), used in clinical 
practice to assess tumor aggressiveness. Empty tumors 
showed moderate tumor cellularity, predominantly com-
posed by epithelioid round cells with respect to spindle 
cells, and thin bands of hyaline collagenous-like matrix. 
Ki-67 label index ranged from 15 to 24%. NF-YAl over-
expression formed tumor tissue with moderate to mild 
cellularity. Scattered round cells and occasionally spin-
dle cells with inconspicuous nuclei were observed in the 
stromal background. Ki-67 label index ranged from 5 to 
Fig. 4 Effect of CRISPR-Cas9-mediated knock out of endogenous NF-YA in NF-YAs-overexpressing PC3 cells. A Western blot analysis of NF-YA 
isoforms in total cellular extracts from NF-YAs and NF-YAs-only (CRISPR-Cas9 edited clone #11 and #23) PC3 cells. Tubulin was used as loading 
control. B Optical microscopy images representative of the morphology of two different NF-YAs clones cultured as MTSs. The arrows indicate 
structures budding from MTS core. Scale bar 4X = 500 μm, scale bar 10X = 250 μm. C Rate of growth (%) of xenograft tumors measured for 5 
consecutive weeks from s.c. inoculation of NF-YAs and NF-YAs-only edited PC3 cells into SCID Hairless Outbred (SHO®) mice. Data represent 
mean ± SEM (Two-way ANOVA with Holm-Sidak’s test n = 4)
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Fig. 5 Expression profiles of NF-YAs and NF-YAl overexpressing MTSs. A Top 25 enriched GO terms of up regulated genes in NF-YAl (left panel) and 
NF-YAs (right panel) overexpressing PC3 MTSs versus Empty control ones. The size of each circle represents the number of genes included in each 
GO term and the color of the circle indicates the adjusted p value. B Comparison of gene expression signatures between NF-YAl vs NF-YAs MTSs 
and Localized vs Benign prostate tissues [38] by RRHO analysis. C Comparison of gene expression signatures between NF-YAl vs NF-YAs MTSs and 
Metastatic vs Localized prostate tissues [38] by RRHO analysis
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17%. Differently, NF-YAs tumors showed highly cellular 
tissue composed by epithelioid elements with irregular 
large nuclei and evident nucleoli close to each other’s 
with no stroma in the peripheral layer, where Ki-67 label 
index ranged from 28 to 67%, corroborating a high pro-
liferative activity. Next to the outer proliferative rim, a 
necrotic core was evident, which can result from rapid 
tumor cell growth and correlates with adverse outcomes 
in numerous solid tumors [41–43]. We further analyzed 
other markers related to tumor progression by western 
blot analysis of total extracts from xenografts (Fig.  6D). 
An increase in AKT and its phosphorylated form, both 
correlated with aggressive cancer [44, 45], was evident 
in NF-YA overexpressing tumors, particularly in NF-YAs 
ones.
Despite subcutaneous PC3-xenografts should not 
yield metastatic lesions within 5 weeks [46], qPCR-
mediated amplification of human specific-Alu 
sequences was used to detect possible disseminated 
human tumor cells within lungs from tumor-bear-
ing mice. As expected, no amplification of human 
genomic DNA was obtained from lungs of mice after 
s.c. injection of control Empty PC3 cells. Differently, 
we observed Alu-positive cells in lungs of 2 and 4 out 
of 8 mice after injection with NF-YAs and NF-YAl cells, 
respectively (Fig. 6E).
RNA extraction from xenograft tumors followed by 
RT-qPCR on selected genes that participate to PCa met-
astatization showed a significant transcriptional modula-
tion in both NF-YAs and NF-YAl samples compared to 
Empty tumors (Fig. 6F).
These results suggest that NF-YA overexpression does 
not favor tumor formation, rather confers aggressive 
hallmarks to established tumors with NF-YAs enhancing 
proliferation and NF-YAl favoring cell dissemination.
NF‑YAs and NF‑YAl overexpression leads to different 
invasive behaviors
The unexpected higher disseminating ability of NF-YAl 
vs NF-YAs cells in xenografts hinted at a more impor-
tant role for NF-YAl in the multi-step metastatic process 
compared to NF-YAs cells. Therefore, we performed cell 
migration and invasion in  vitro assays to compare NF-
YAl and NF-YAs pro-metastatic activities. Boyden cham-
ber assays showed increased ability of single cell motility 
toward a chemo-attractant gradient in NF-YAl-cells 
(Fig.  7A). Besides, in wound healing 2D assay, NF-YAl 
cells closed the gap faster than NF-YAs cells (Fig. 7B).
We then analyzed size and shape in 3D ECM spheroid 
invasion assays. PC3 aggregates were included in 1 mg/
ml growth factors-enriched Matrigel, which allowed both 
proliferation and invasion. Optical microscopy showed 
that some cells leave the core of Matrigel-embedded 
MTSs, forming a more evident invasion zone in NF-YAs 
and NF-YAl compared to Empty spheroids (Fig. 7C). Addi-
tionally, we studied the invasive behavior of MTSs when 
embedded into 5 mg/ml growth factors-reduced Matrigel 
and surrounded by high-serum culture medium as chemo-
attractant (Fig.  7D). The results showed that NF-YAl 
induces the formation of multicellular strands radiating 
from the periphery of the spheroid, with sunburst pat-
tern similarly to Empty MTSs. Differently, NF-YAs MTSs 
have an expansive ring-like budding phenotype, as already 
observed in 3D growth condition (Fig. 3H).
Overall, both NF-YA isoforms could contribute to 
tumor invasion, but only NF-YAl increase enhances cell 
migration.
NF‑YAs expression predicts the clinical outcome of PCa 
patients
These results prompted us to analyze the levels of NF-
YAs and NF-YAl transcripts in patients affected by 
metastatic CRPCs [47] compared to primary adenocar-
cinomas. The ratio between NF-YAs/NF-YAl did not 
decrease in metastatic disease, independently from the 
(See figure on next page.)
Fig. 6 Effect of NF-YAs and NF-YAl overexpression on tumor growth and cell dissemination in vivo. A Weight (mg) of xenograft tumors at 5 weeks 
from s.c. inoculation of Empty, NF-YAl and NF-YAs PC3 cells into SCID Hairless Outbred (SHO®) mice. Data represent mean ± SEM (one-way ANOVA 
with Fisher’s LSD test: *p < 0.05, ns, not significant, n = 8). B Rate of growth (%) of Empty, NF-YAs and NF-YAl xenograft tumors at the indicated 
time points following s.c. inoculation of transduced PC3 cells. Data represent mean ± SEM (two-way ANOVA with Holm-Sidak’s test: *p < 0.05, 
n = 8) C Representative H&E-stained FFPE sections of 5 weeks xenograft tumors at low (left panel) and high (middle panel) magnifications. 
Immunohistochemical detection of Ki67 in xenograft tumors (right panel). D Western blot of total extracts from PC3 tumor xenograft with the 
indicated antibodies. Tubulin has been used as loading control. Quantification of band intensities was performed with ImageJ software and relative 
phospho-AKT(Ser473) levels are indicated, after normalization to Tubulin and AKT expression (E) Representation of the incidence of spontaneous 
cell dissemination to lung tissue in mice after 5 weeks from s.c. injection of Empty, NF-YAl, NF-YAs PC3 cells. Cell dissemination has been identified 
by the detection of human genomic DNA through Alu-qPCR in mouse lung tissues. F RT-qPCR analysis of the indicated transcripts in xenograft 
tumors harvested following 5 weeks from s.c. injection. Rps20 and b-Actin were used as reference genes and normalized mRNA levels are reported 
as fold change vs Empty biological group, arbitrarily set at 1. Data represent mean ± SEM (one-way ANOVA with Tukey’s test: *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001, n = 5)
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Fig. 7 Activity of NF-YAs and NF-YAl overexpression in cell migration and 3D invasion. A Percentage of cell migration of Empty, NF-YAl and NF-YAs 
cells measured by transwell assay. Data represent mean ± SEM (one-way ANOVA with Fisher’s LSD test: *p < 0.05, **p < 0.01, ns, not significant, 
n = 4). B Confluent cells were seeded into Ibidi wound-healing chambers and images were acquired at 0, 18, 20 and 22 h after the culture chambers 
were removed. (Left panel) Quantification of migration is shown as residual wound area compared to the initial gap, arbitrarily set at 100%. Data 
represent mean ± SEM (two-way ANOVA with Fisher’s LSD test: *p < 0.05, **p < 0.01 n = 6). (Right panel) Representative images of cell migration 
in wound-healing assay. C (Left panel) Representative phase contrast microscopy images of Empty, NF-YAl and NF-YAs MTSs. Spheroid invasion 
of MTSs included for 7 days in 1 mg/ml growth factors-enriched Matrigel. (Right panel) The histogram represents the percentage of invasion 
area vs total area of MTSs. Data represent mean ± SEM (unpaired t-test: *p < 0.05, ns, not significant, n = 3). D Phase contrast microscopy images 
representative of the invasive behaviour of MTSs when embedded into 5 mg/ml growth factors-reduced Matrigel surrounded by high-serum 
culture medium as chemoattractant for 7 and 11 days (n = 4). Scale bar = 500 μm
(See figure on next page.)
Fig. 8 Lower NF-YAs/NF-YAl ratio distinguishes PCa CTCs from Met. CRPC and high NF-YAs predicts the clinical outcome of PCa patients. A Left 
panel: Ratio of NF-YAs/NF-YAl transcripts in Met. CRPC samples compared to TCGA primary adenocarcinomas. Box plots were obtained following 
log2 transformation of TPM and z-score normalization of processed datasets. Right panel: Ratio of NF-YA isoforms in Met. CRPC samples compared 
to PCa CTCs. Raw counts of both datasets were normalized with DESeq2 algorithm and the Variance Stabilizing Transformed (vst) is represented. 
B Log transformed TPM and z-score normalization of NF-YAs/NF-YAl ratio in PRAD samples, stratified according to PAM50 subtypes. Wilcoxon test: 
****p < 0.0001, ns, not significant. C, D Kaplan-Meier analysis of progression-free interval (PFI) in TCGA PRAD patients stratified according to high 
and medium/low expression of NF-YAs and NF-YAl, respectively. P values for the log rank tests are indicated. E Univariable and multivariable hazard 
ratio (HR) analyses of different prognostic parameters and NF-YAs expression in PRAD patients. Left table includes all patients; right table includes a 
subset of patients who have received either radiotherapy or chemotherapy
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metastatic site, ruling out that NF-YAl increase could 
induce metastatic colonization of other tissues (Fig. 8A, 
left panel and Suppl. Fig.  6C). Since our in  vitro and 
in vivo results clearly indicated a possible role of NF-YAl 
in cell migration, we decided to explore RNA-seq data of 
CTCs (circulating tumor cells). Although data were avail-
able only from few patients [48], the results showed a sig-
nificant reduction in NF-YAs/NF-YAl ratio compared to 
metastatic samples (Fig. 8A, right panel), supporting our 
hypothesis that increased NF-YAl could enhance migrat-
ing abilities of PCa cells.
To investigate a possible application of NF-YA splic-
ing signature in stratification of PCa patients, we used a 
transcriptome-based classification method associated 
with clinical behavior [5, 49–51]. We applied the PAM50 
algorithm to identify whether the NF-YA splicing signa-
ture is altered in previously characterized luminal- and 
basal-like PCa subtypes that show differences in clinical 
outcomes and treatment response [5]. In opposition to 
NF-YAl, NF-YAs is particularly high in LumB subtype, 
which has the poorest prognosis even with low Gleason 
sum score (GS < 7) and is characterized by a proliferative 
signature [5, 6] (Fig. 8B).
We then decided to determine whether the expres-
sion of NF-YA splice variants can be used as a prognos-
tic marker for PCa. In PRAD TCGA studies survival 
analyses were not reported, therefore the use of progres-
sion-free interval (PFI) from prostatectomy has been 
recommended [52]. Stratification on the basis of high or 
medium/low NF-YAs expression highlighted a significant 
poorest clinical prognosis of PCa patients characterized 
by high NF-YAs expression (Fig.  8C). Despite not sig-
nificant, lower PFI was observed in medium/low NF-YAl 
patients up to 4 years (Fig.  8D). Next, we used the Cox 
proportional-hazards model for investigating the associa-
tion between the survival time of patients, represented by 
hazard ratio (HR), and NF-YAs expression together with 
PSA (ng/ml), PCS and PAM50 variables. Higher NF-YAs 
levels significantly increase HR both in TCGA cohort 
that includes all PCa patients (Fig. 8E, left panel) and in 
the sub-cohort consisting of patients treated with phar-
macological or radiation therapy (Fig. 8E, right panel).
These results further corroborate that high level of 
NF-YAs transcript is a significant independent prognos-
tic factor associated with poor clinical outcome in PCa 
patients.
Discussion
PCa disease is characterized by extreme clinical hetero-
geneity and unpredicted therapeutic response of patients. 
The transcriptional profile of PCa is different from the 
majority of tumors, being an indolent and slow-prolif-
erating cancer in which cell growth and cell cycle gene 
categories are not retrieved among up-regulated terms. 
Despite this, large-scale analyses identified NF-Y among 
TFs involved in molecular networks inducing the pro-
gression from benign epithelium to both localized and 
hormone-refractory metastatic PCa [7]. Moreover, NF-Y 
has been listed among TF coordinated groups (TFCGs) 
that characterize the differential transcriptional signa-
ture in tumors of patients treated with ADT, which is 
enriched in genes that drive metastasis [50].
Data analysis from TCGA database highlights the 
increase in total NF-YA gene transcription in PCa com-
pared to healthy tissues, in particular in high GS samples. 
This increase is associated to the up-regulation of the 
NF-YAs isoform, while NF-YAl transcript decreases. Of 
particular relevance is the demonstration that changes in 
the expression of NF-YA isoforms are associated to key 
clinical and molecular features of aggressive PCa. The 
ratio between NF-YAs and NF-YAl increases in higher 
GS adenocarcinomas and in luminal B/PCS1 tumor sub-
type, which includes tumors with the poorest outcome 
with GS ≥ 8 but also with GS ≤ 7 associated to metastatic 
progression [6] (Figs. 1 and 8).
In vivo analysis of the effects of NF-YA overexpression 
on tumor growth led to unexpected results: although 
increased NF-YAs levels should enhance tumor progres-
sion, NF-YAs xenograft tumors showed reduced vol-
ume compared to control tumors. A similar behavior 
was observed for NF-YAl xenografts. Mass spectrom-
etry technique has recently demonstrated that very few 
injected cells initiate the tumor regardless of the quan-
tity of delivered cells, which showed more than 95% cell 
death [40]. Since s.c. tumors are formed by a very small 
population of tumor initiating cells, the reduced clono-
genic ability induced by both NF-YAs and NF-YAl over-
expression could affect tumor engrafment (Fig. 6).
Because of ethical issues, we could not follow tumor 
growth beyond week 5. Therefore, we performed histo-
logical analysis of xenograft tumors to better character-
ize the effect of NF-YA overexpression on tumor growth. 
NF-YAs tumors showed a highly Ki67+ proliferative rim 
and an internal necrotic core. The presence of necro-
sis within tumors is controversial: on one hand necro-
sis supports shrinkage of tumor mass and consequently 
appears as a favorable characteristic, on the other hand 
necrosis promotes tumor progression and aggressiveness 
and is considered as a negative prognostic factor (for a 
review see [41]). Western blot analysis on xenograft total 
extracts identified an increase in phospho-AKT particu-
larly in NF-YAs tumors, suggesting once again a more 
aggressive phenotype.
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MTSs, models for self-assembled cell aggregates, 
came in support to better elucidate whether NF-YAs 
overexpression can sustain tumor aggressiveness, as 
suggested by TCGA transcriptional data from PCa 
patients. A significant increase in BrdU+ cells demon-
strates the enhanced proliferative ability conferred by 
NF-YAs to tumor cells compared to both Empty and 
NF-YAl cells, accompanied by reduced cell death deter-
mined by Annexin V staining. Surprisingly, no categories 
associated to cell proliferation or cell cycle progression 
are observed in highly proliferative NF-YAs tumors, 
although these terms are usually described as up-regu-
lated by NF-YA overexpression [15–17, 20]. The main 
up-regulated GO terms are associated to ECM organiza-
tion, which could account for evident changes in MTSs 
morphology. Tumor progression demands continu-
ous interactions between ECM and tumor cells, which 
secrete matrix-metalloproteinases (MMPs), fibronectin 
and collagens that interfere with cell-cell adhesion and 
cell polarity [53]. Consistently, many genes belonging to 
these categories transcriptionally increase in NF-YAs-
xenograft tumors. Despite this, cell migration does not 
seem to characterize NF-YAs cells but NF-YAl ones, at 
least when analyzed by 2D wound healing and transwell-
migration assays (Fig. 7). When cultured in 3D, NF-YAl 
cells show sprouting cells associated to reduced MTS 
dimension, while NF-YAs cells form bigger MTSs charac-
terized by ring-like structures from which some cells can 
sprout, in particular at later time points. These results 
would suggest that NF-YAs has mainly a pro-proliferative 
activity, but once cell–cell and cell–matrix interactions 
occur, it could confer invasive properties too.
Taking into consideration that high NF-YAs/NF-YAl 
ratio characterizes both primary tumors and metastatic 
ones, we hypothesized that high NF-YAs is a condition 
necessary to allow tumor cell expansion locally as well as 
in distant metastasis, while NF-YAl could be required for 
short-time specific invasive behaviors, such as migrating 
abilities. Indeed, the metastatic process requires three 
consecutive steps: firstly, neoplastic cells break down the 
basement membrane of tumor blood vessels, allowing 
stroma invasion and intravasation. Afterwards, the cells 
have to survive through the circulation and they finally 
extravasate in a distant organ, where they adapt and start 
to proliferate [54]. The profile of circulating tumor cells 
(CTCs) from CRPC patients supported our hypothesis 
Fig. 9 Schematic representation of biological properties of PCa cells overexpressing different NF-YA isoforms. Localized and metastatic PCa tumors 
are mainly composed by cells expressing high levels of NF-YAs (NF-YAshigh), which is fundamental for their survival and enhances proliferation 
and interaction with ECM. Both NF-YAshigh and NF-YAlhigh cells are able to invade ECM with different patterns and form distant lung metastases. 
NF-YAlhigh cells have increased migration ability, consistently with higher NF-YAl expression in PCa CTCs. Stratification of patients based on 
NF-YAshigh signature predicts poor clinical outcome. Created with BioRe nder. com (Biorender, RRID:SCR_018361)
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(Fig. 8). Although very few datasets from PCa CTCs are 
available and the majority of these data do not satisfy 
the criteria to allow the analysis of alternatively spliced 
transcripts [55–57], we were able to obtain preliminary 
results from a little cohort of patients [48]. The signifi-
cant decrease in NF-YAs/NF-YAl ratio in CTCs com-
pared to both primary and metastatic PCa, corroborate 
that higher NF-YAl expression can confer cell migration 
ability even in PCa patients.
PFI and regression analyses highlight the clinical sig-
nificance of our studies. In particular, we propose the 
analysis of NF-YAs levels as a new molecular strat-
egy for risk assessment in PCa patients. High NF-YAs 
expression is associated with PCa outcome, indepen-
dently of other clinical variables. Optimal manage-
ment of PCa is majorly associated to the diagnostic 
process rather than the selection of appropriate active 
treatment. While Gleason score, TNM staging and 
pre-treatment PSA values provide key prognostic infor-
mation on the expected behaviour of the tumor, they 
don’t always allow to discriminate biologically aggres-
sive tumors (for a review see [58]).
In this scenario, NF-YAs can represent a new bio-
marker for stratification of PCa patients (Fig.  9). Fur-
ther studies will allow to investigate whether NF-YA 
splicing signature can improve active surveillance in 
low-risk PCa or properly classify aggressive cancers 
erroneously defined as “intermediate” risk on the basis 
of tumor biopsy, thus avoiding both over- or under-
treatment. Finally, a deepen analysis of NF-YA splicing 
in CTCs will give new insights on the role of NF-Y in 
conferring ability to the cells to survive in the periph-
eral blood, resistance to anoikis, escape of immune sur-
veillance and resistance to chemotherapy.
Conclusions
Regulation of the splicing process of the NF-YA subu-
nit of the transcription factor NF-Y is highly relevant 
for understanding PCa hallmarks. Unbalanced NF-YAs/
NF-YAl ratio is associated not only to localized adeno-
carcinoma, but also to metastatic PCa that eventu-
ally develops resistance to therapies. Evaluation of the 
expression of NF-YA isoforms may be adopted as a 
new strategy for risk stratification of PCa patients and 
can be useful for defining biological properties of PCa 
(Fig. 9).
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Additional file 1: Suppl. Figure S1. Effects of NF-YA inactivation by RNAi 
in vitro and in vivo. (A) Cell proliferation curve measured by MTT assay 
of PC3 cells infected with scramble (shCTR) and NF-YA-targeting shRNA 
(shNF-YA). Data represent mean ± SEM (multiple t-test corrected by the 
Holm-Sidak method: *p<0.05, **p<0.01, n=4). (B) Images of xenograft 
tumors dissected from SCID Hairless Outbred (SHO®) mice after 5 weeks 
from s.c. injection of shCTR and shNF-YA cells (7 mice per group).
Additional file 2: Suppl. Figure S2. Effects of the overexpression of 
NF-YA isoforms in PCa cell lines. (A) Validation of the overexpression of 
NF-YAl and NF-YAs by western blot of whole cell extracts from LNCaP 
stable cell lines. Tubulin was used as loading control. (B) Colony number of 
Empty, NF-YAl and NF-YAs LNCaP cells cultured in anchorage-dependent 
growth condition. Data represent mean ± SEM (one-way ANOVA with 
Fisher’s LSD test: *p<0.05, ***p<0.001, n=3). (C) Colony number of Empty, 
NF-YAl and NF-YAs LNCaP cells cultured in anchorage-independent 
growth condition. Data represent mean ± SEM (one-way ANOVA with 
Fisher’s LSD test: *p<0.05, ns, not significant, n=6). (D) Time course analysis 
of cellular growth of LNCaP cultured as MTSs, calculated as projected 
area fold change relative to day 2, arbitrarily set at 1. Data represent 
mean ± SEM (two-way ANOVA with Holm-Sidak’s test: *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, n=3). (E) Western blot analysis of NF-YA expres-
sion in Empty, NF-YAl and NF-YAs DU145 stable cell lines. Tubulin was used 
as loading control. (F) Time course analysis of cellular growth of DU145 
cultured as MTSs, calculated as projected area fold change relative to 
day 4, arbitrarily set at 1. Data represent mean ± SEM (two-way ANOVA 
with Holm-Sidak’s test: *p<0.05, **p<0.01, n=4). (G) Western blot of total 
extracts from PC3 MTSs with the indicated antibodies. Tubulin has been 
used as loading control.
Additional file 3: Suppl. Figure S3. CRISPR/Cas9-mediated knock out 
of endogenous hNF-YA. (A) Schematic representation of CRISPR/Cas9 
strategy to knock down human NF-YA. The picture illustrates the sgRNA 
targeting endogenous hNF-YA (blue line) and the PAM sequence specific 
for the human gene (red line). Sequence alignment of the reverse comple-
mentary strand of exon 2 of human and mouse NF-YA gene is shown. (B) 
Indel spectrum determined by TIDE analysis on human NF-YA gene in a 
representative experiment of bulk CRISPR-treated PC3 cells overexpress-
ing murine NF-YAl (left panel) or NF-YAs (right panel). Editing frequencies 
are shown (p < 0.05). (C) Indel spectrum determined by TIDE analysis on 
murine NF-YA in CRISPR-treated and GFP-sorted PC3 cells overexpress-
ing murine NF-YAl (left panel) or NF-YAs (right panel). (D) Indel spectrum 
determined by TIDE analysis on human NF-YA gene in PC3 NF-YAs clone 
#11 (left panel) or #23 (right panel). Frequencies of editing are reported (p 
< 0.05) and show biallelic editing.
Additional file 4: Suppl. Figure S4. Gene signature of MTSs overexpress-
ing NF-YAs or NF-YAl. Top 25 enriched GO terms of down regulated genes 
in NF-YAl (left panel) and NF-YAs (right panel) overexpressing PC3 MTSs 
vs Empty control ones. The size of each circle represents the number of 
genes included in each GO term and the color of the circle indicates the 
adjusted p value.
Additional file 5: Suppl. Figure S5. Unique gene signature of MTSs 
overexpressing NF-YAs or NF-YAl. (A) Top 25 enriched GO terms of up and 
down regulated genes in NF-YAl overexpressing cells vs Empty cells by 
setting |Log2FC| >1 and discarding genes with |Log2FC| >0.5 in NF-YAs 
vs Empty. (B) Top 25 enriched GO terms of up and down regulated genes 
in NF-YAs overexpressing cells vs Empty cells by setting |Log2FC|>1 and 
discarding genes with |Log2FC| >0.5 in NF-YAl vs Empty. The size of each 
circle represents the number of genes enriched in each GO term. Color 
bar indicates adjusted p-value for the labeled GO term.
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Additional file 6: Suppl. Figure S6. Effect of NF-YA overexpression on 
tumor growth in vivo and analysis of NF-YA isoforms in PCa metastatic 
sites. (A) Volumes  (mm3) of Empty, NF-YAs and NF-YAl xenograft tumors at 
the indicated time points. Data represent mean ± SEM (two-way ANOVA 
with Holm-Sidak’s test: *p<0.05, **p<0.01, ns, not significant, n=8). (B) 
Images of xenograft tumors dissected from SCID Hairless Outbred (SHO®) 
mice after 5 weeks from s.c. injection. (C) Analysis of NF-YAs and NF-YAl 
transcripts in metastatic sites from PCa samples (GEO147250) and TCGA 
dataset (Prostate primary).
Additional file 7: Table S1. Oligonucleotides used in the experiments.
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